Cervical cancer is the third most common cancer in women worldwide. Persistent infection with high-risk HPV types, principally HPV16 and 18 is the main risk factor for the development of this malignancy. However, the onset of invasive tumor occurs many years after initial exposure in a minority of infected women. This suggests that other factors beyond viral infection are necessary for tumor establishment and progression. Tumor progression is characterized by an increase in secretion and activation of matrix metalloproteinases (MMPs) produced by either the tumor cells themselves or tumor-associated fibroblasts or macrophages. Increased MMPs expression, including MMP-2, MMP-9 and MT1-MMP, has been observed during cervical carcinoma progression. These proteins have been associated with degradation of ECM components, tumor invasion, metastasis and recurrence. However, few studies have evaluated the interplay between HPV infection and the expression and activity of MMPs and their regulators in cervical cancer. We analyzed the effect of HPV16 oncoproteins on the expression and activity of MMP-2, MMP-9, MT1-MMP, and their inhibitors TIMP-2 and RECK in cultures of human keratinocytes. We observed that E7 expression is associated with increased pro-MMP-9 activity in the epithelial component of organotypic cultures, while E6 and E7 oncoproteins co-expression down-regulates RECK and TIMP-2 levels in organotypic and monolayers cultures. Finally, a study conducted in human cervical tissues showed a decrease in RECK expression levels in precancer and cancer lesions. Our results indicate that HPV oncoproteins promote MMPs/RECK-TIMP-2 imbalance which may be involved in HPV-associated lesions outcome.
References
[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) CA Cancer J Clin Mar–Apr;61(2): 69–90. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin 2011 Mar–Apr;61(2):134.
[2]
International Agency for Research on Cancer/World Health Organization (2007) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses. Vol. 90. Lyon: IARC Press. Available: http://www-dep.iarc.fr/. Accessed 2011 Oct 01.
[3]
Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, et al. (2001) Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA Dec 26;286(24): 3106–14.
[4]
McLaughlin-Drubin ME, Münger K (2009) Oncogenic activities of human papillomaviruses. Virus Res Aug;143(2): 195–208. Epub 2009 Jun 18. Review.
[5]
Howie HL, Katzenellenbogen RA, Galloway DA (2009) Papillomavirus E6 proteins. Virology Feb 20;384(2): 324–34. Epub 2008 Dec 10. Review.
[6]
Goodwin EC, DiMaio D (2000) Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci U S A Nov 7;97(23): 12513–8.
[7]
Goodwin EC, Yang E, Lee CJ, Lee HW, DiMaio D, et al. (2000) Rapid induction of senescence in human cervical carcinoma cells. Proc Natl Acad Sci U S A Sep 26;97(20): 10978–83.
[8]
Sternlicht MD, Bissell MJ, Werb Z (2000) The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene Feb 21;19(8): 1102–13. Review.
[9]
Stetler-Stevenson WG (2008) The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev Mar;27(1): 57–66. Review.
[10]
Egeblad M, Werb Z (2002) New Functions for the Matrix Metalloproteínases in Cancer Progression. Nature Reviews Cancer 2: 161–74.
[11]
Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell Apr 2;141(1): 52–67. Review.
[12]
Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, et al. (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107(6): 789–800.
[13]
Sasahara RM, Brochado SM, Takahashi C, Oh J, Maria-Engler SS, et al. (2002) Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. Cancer Detect Prev 26(6): 435–43.
[14]
Takagi S, Simizu S, Osada H (2009) RECK negatively regulates matrix metalloproteínase-9 transcription. Cancer Res Feb 15;69(4): 1502–8. Epub 2009 Feb 10.
[15]
Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, et al. (1998) Regulation of matrix metalloproteínase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A 95(22): 13221–6.
[16]
Furumoto K, Arii S, Mori A, Furuyama H, Gorrin Rivas MJ, et al. (2001) RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing–cysteine-rich protein with Kazal motifs. Hepatology 33(1): 189–95.
[17]
Span PN, Sweep CG, Manders P, Beex LV, Leppert D, et al. (2003) Matrix metalloproteínase inhibitor reversion-inducing cysteine-rich protein with Kazal motif a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97(11): 2710–5.
[18]
Masui T, Doi R, Koshiba T, Fujimoto K, Tsuji S, et al. (2003) RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Can Res 9: 1779–1784.
[19]
Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, et al. (2004) The membrane-anchored matrix metalloproteínase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10(16): 5572–9.
[20]
Takenaka K, Ishikawa S, Kawano Y, Yanagihara K, Miyahara R, et al. (2004) Expression of a novel matrix metalloproteínase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer 40(10): 1617–23.
[21]
Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, et al. (2005) Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer Jun 20;92(12): 2171–80.
[22]
Dong Q, Yu D, Yang CM, Jiang B, Zhang H (2010) Expression of the reversion-inducing cysteine-rich protein with Kazal motifs and matrix metalloproteinase-14 in neuroblastoma and the role in tumour metastasis. Int J Exp Pathol Aug;91(4): 368–73. Epub 2010 Jun 24.
[23]
Clark JC, Thomas DM, Choong PF, Dass CR (2007) RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev Dec;26(3–4): 675–83. Review.
[24]
Nuovo GJ, MacConnell PB, Simsir A, Valea F, French D (1995) Correlation of the in Situ Detection of Polymerase Chain Reaction-amplified Metalloproteínase Complementary DNAs and Theirs Inhibitors with Prognosis in Cervical Carcinoma. Cancer Res 55: 267–75.
[25]
Brummer O, Bohmer G, Hollwitz B, Flemming P, Petry KU, et al. (2002) MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation–an immunohistochemical study. Gynecol Oncol 84(2): 222–7.
[26]
Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, et al. (2003) Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 63: 6537–42.
[27]
Gaiotto MA, Focchi J, Ribalta JL, Stavale JN, Baracat EC, et al. (2004) Comparative study of MMP-2 (matrix metalloproteínase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. Am J Obstet Gynecol May 190(5): 1278–82.
[28]
Zhai Y, Hotary KB, Nan B, Bosch FX, Mu？oz N, et al. (2005) Expression of membrane type 1 matrix metalloproteínase is associated with cervical carcinoma progression and invasion. Cancer Res Aug 1 65(15): 6543–50.
[29]
da Silva Cardeal LB, Brohem CA, Correa TC, Winnischofer SM, Nakano F, et al. (2006) Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. Biochem Cell Biol Oct;84(5): 713–9.
[30]
Min W, Wen-li M, Zhao-hui S, Ling L, Bao Z, et al. (2009) Microarray analysis identifies differentially expressed genes induced by human papillomavirus type 18 E6 silencing RNA. Int J Gynecol Cancer May;19(4): 547–63.
[31]
Boccardo E, Noya F, Broker TR, Chow LT, Villa LL (2004) HPV-18 confers resistance to TNF-alpha in organotypic cultures of human keratinocytes. Virology Oct 25;328(2): 233–43.
[32]
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(？Delta Delta C(T)) Method. Methods Dec 25(4): 402–8.
[33]
Théret N, Lehti K, Musso O, Clément B (1999) MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology Aug;30(2): 462–8.
[34]
Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, et al. (2008) Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia Apr;10(4): 329–40.
[35]
Schr？er N, Pahne J, Walch B, Wickenhauser C, Smola S (2011) Molecular pathobiology of human cervical high-grade lesions: paracrine STAT3 activation in tumor-instructed myeloid cells drives local MMP-9 expression. Cancer Res Jan 1;71(1): 87–97.
[36]
Akgül B, García-Escudero R, Ekechi C, Steger G, Navsaria H, et al. (2011) The E2 protein of human papillomavirus type 8 increases the expression of matrix metalloproteinase-9 in human keratinocytes and organotypic skin cultures. Med Microbiol Immunol May;200(2): 127–35. Epub 2011 Jan 28.
[37]
Yoshida S, Kajitani N, Satsuka A, Nakamura H, Sakai H (2008) Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins. J Virol Sep 82(17): 8820–7. Epub 2008 Jun 25.
[38]
Nair A, Karunagaran S, Nair MB, Sudhakaran PR (2003) Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol Feb129(2): 123–31.
[39]
Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, et al. (2006) Matrix metalloproteínase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. Anticancer Res Mar–Apr;26(2B): 1543–56.
[40]
Fejzo MS, Ginther C, Dering J, Anderson L, Venkatesan N, et al. (2011) Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK. Genes Chromosomes Cancer Jun;50(6): 434–41. doi:10.1002/gcc.20868. Epub 2011 Mar 22.
[41]
Morioka Y, Monypenny J, Matsuzaki T, Shi S, Alexander DB, et al. (2009) The membrane-anchored metalloproteínase regulator RECK stabilizes focal adhesions and anterior-posterior polarity in fibroblasts. Oncogene Mar 19;28(11): 1454–64. Epub 2009 Jan 26.
[42]
Silveira Corrêa TC, Massaro RR, Brohem CA, Taboga SR, Lamers ML, et al. (2010) RECK-mediated inhibition of glioma migration and invasion. J Cell Biochem May;110(1): 52–61.
[43]
Oh J, Seo DW, Diaz T, Wei B, Ward Y, et al. (2004) Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res Dec 15;64(24): 9062–9.
[44]
Oh J, Diaz T, Wei B, Chang H, Noda M, et al. (2006) TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene Jul 13;25(30): 4230–4. Epub 2006 Feb 20.
[45]
Liu LT, Peng JP, Chang HC, Hung WC (2003) RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene Nov 13 22(51): 8263–70.
